Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.
The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.
Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Probenecid | The serum concentration of Latamoxef can be increased when it is combined with Probenecid. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Latamoxef. |
| Tenofovir disoproxil | Latamoxef may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Latamoxef may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Latamoxef may increase the nephrotoxic activities of Tenofovir. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Latamoxef. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Latamoxef. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Latamoxef. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Latamoxef. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Latamoxef. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Latamoxef. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Latamoxef. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Latamoxef. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Latamoxef. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Latamoxef. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Latamoxef. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Latamoxef. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Latamoxef. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Latamoxef. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Latamoxef. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Latamoxef. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Latamoxef. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Latamoxef. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Latamoxef. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Latamoxef. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Latamoxef. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Latamoxef. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Latamoxef. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Latamoxef. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Latamoxef. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Latamoxef. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Latamoxef. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Latamoxef. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Latamoxef. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Latamoxef. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Latamoxef. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Latamoxef is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Latamoxef. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Latamoxef. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Latamoxef. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Latamoxef. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Latamoxef. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Latamoxef. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Latamoxef. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Latamoxef. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Latamoxef. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Latamoxef. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Latamoxef. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Latamoxef. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Latamoxef. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Latamoxef. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Latamoxef. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Latamoxef. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Latamoxef. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Latamoxef. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Latamoxef. |
| Cefoxitin | The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Latamoxef. |
| Ceftizoxime | The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Latamoxef. |
| Magnesium salicylate | The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Latamoxef. |
| Salsalate | The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Latamoxef. |
| Choline magnesium trisalicylate | The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Latamoxef. |
| Cefepime | The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Latamoxef. |
| Cefacetrile | The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Latamoxef. |
| Cefpodoxime | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Latamoxef. |
| Antrafenine | The risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Latamoxef. |
| Aminophenazone | The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Latamoxef. |
| Antipyrine | The risk or severity of nephrotoxicity can be increased when Antipyrine is combined with Latamoxef. |
| Tiaprofenic acid | The risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Latamoxef. |
| Lopinavir | The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Latamoxef. |
| Etoricoxib | The risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Latamoxef. |
| Hydrolyzed Cephalothin | The risk or severity of nephrotoxicity can be increased when Hydrolyzed Cephalothin is combined with Latamoxef. |
| Cephalothin Group | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Latamoxef. |
| Oxyphenbutazone | The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Latamoxef. |
| Nimesulide | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Nimesulide. |
| Benoxaprofen | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Benoxaprofen. |
| Metamizole | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Metamizole. |
| Zomepirac | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Zomepirac. |
| Ceftobiprole | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Ceftobiprole. |
| Cimicoxib | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Cimicoxib. |
| Ceftaroline fosamil | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Ceftaroline fosamil. |
| Lornoxicam | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Lornoxicam. |
| Zaltoprofen | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Zaltoprofen. |
| Azapropazone | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Azapropazone. |
| Parecoxib | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Parecoxib. |
| Salicylamide | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Salicylamide. |
| Kebuzone | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Kebuzone. |
| Isoxicam | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Isoxicam. |
| Indoprofen | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Indoprofen. |
| Ibuproxam | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Ibuproxam. |
| Floctafenine | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Floctafenine. |
| Fenbufen | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Fenbufen. |
| Etofenamate | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Etofenamate. |
| Epirizole | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Epirizole. |
| Cefaloridine | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Cefaloridine. |
| Cefminox | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Cefminox. |
| Dexibuprofen | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Dexibuprofen. |
| Droxicam | The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Droxicam. |